Hemophilia A and B patients who use marstacimab have less annualized bleeding.

Published Date: 11 Jan 2024

Pfizer reports that in hemophilia A and B patients without inhibitors, marstacimab decreased the annualized bleeding rate (ABR) by 35 percent and nearly 92 percent, respectively, in comparison to routine prophylaxis and on-demand treatment.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.

2.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

3.

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

4.

Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma

5.

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot